EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieOpen Access · CC BY 4.0

Comparative effectiveness of echinocandins and liposomal amphotericin B for fluconazole-resistant Candida parapsilosis bloodstream infections

Antonio Vena iD, Claudia Bartalucci iD, Marco Muccio, Giusy Tiseo iD, Patricia Muñoz iD, Mario Cesaretti, Vincenzo Di Pilato iD, Anna Marchese, Ramona Barbieri, Arianna Forniti, Daniele Roberto Giacobbe iD, Alessandro Limongelli und 12 weitere

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00355-25 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Antonio Vena und 23 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, Policlinico San Martino Hospital - IRCCS, Genoa, Italy. Hauptthemen laut MEDLINE: Antifungal Agents, Amphotericin B, Fluconazole, Candida parapsilosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current therapeutic options for fluconazole-resistant Candida parapsilosis (FLZR-CP) bloodstream infections (BSI) are limited to echinocandins and liposomal amphotericin B (L-AmB). To the best of our knowledge, no real-world comparative effectiveness studies have assessed these agents. This study aimed to compare the effectiveness of echinocandins and L-AmB for the treatment of FLZR-CP BSI. This retrospective, observational study was conducted in two hospitals in Italy between January 2018 and December 2022. Eligible patients were adults (≥18 years old) with microbiologically confirmed FLZR-CP BSI who received targeted therapy with either echinocandins or L-AmB. Patients were matched (2:1) based on age, Charlson comorbidity index, presence of sepsis or septic shock, time to appropriate antifungal therapy (≤48 hours or > 48 hours from diagnosis), and infection source. A total of 63 patients were included (42 in the echinocandin group and 21 in the L-AmB group). In Cox regression, targeted therapy with echinocandins was not associated with increased mortality (adjusted hazard ratio 1.40; 95% confidence interval [CI] 0.33–5.92, P = 0.645). An exploratory sensitivity analysis including patients who did not receive source control yielded consistent results ( P = 0.491). Furthermore, in the multivariable regression analysis, echinocandin therapy was not associated with an increased risk of persistent fungemia (adjusted odds ratio 1.61: 95% CI 0.43–5.99, P = 0.476). Treatment with echinocandins and L-AmB resulted in similar 30-day mortality and persistent fungemia rates in patients with FLZR-CP BSI. These findings confirm that echinocandins are a viable treatment option for C. parapsilosis BSI, even for patients with fluconazole-resistant strains.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsAmphotericin BFluconazoleCandida parapsilosisEchinocandinsCandidemiaCandidiasisHumansFemaleMaleRetrospective StudiesMiddle AgedAgedDrug Resistance, FungalMicrobial Sensitivity TestsAdult

Stichwörter der Autor:innen

Candida bloodstream infectionCandida parapsilosisechinocandinsfluconazole resistanceliposomal amphotericin B

Substanzen

Antifungal AgentsAmphotericin Bliposomal amphotericin BFluconazoleEchinocandins

Autor:innen und Institutionen

  • Infectious Diseases Unit, Policlinico San Martino Hospital - IRCCS, Genoa, Italy.
  • Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
  • Infectious Diseases Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
  • Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Instituto de Investigación Sanitaria Hospital Gregorio Marañón, Madrid, Spain.
  • CIBER Enfermedades Respiratorias-CIBERES (CB06/06/0058), Madrid, Spain.

ORCID-Profile: Antonio Vena, Claudia Bartalucci, Giusy Tiseo, Patricia Muñoz, Vincenzo Di Pilato, Daniele Roberto Giacobbe, Antonella Lupetti, Jon Salmanton-García, Ana Soriano Martín, Pilar Escribano, Jesus Guinea, Marco Falcone

Zitieren

APA

Vena, A., Bartalucci, C., Muccio, M., Tiseo, G., Muñoz, P., Cesaretti, M., Di Pilato, V., Marchese, A., Barbieri, R., Forniti, A., Giacobbe, D. R., Limongelli, A., Lupetti, A., Mikulska, M., Salmanton-García, J., Soriano Martín, A., Taramasso, L., Valerio, M., Escribano, P., …, & ESCMID Fungal Infection Study Group (EFISG) (2025). Comparative effectiveness of echinocandins and liposomal amphotericin B for fluconazole-resistant Candida parapsilosis bloodstream infections. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00355-25

Vancouver

Vena A, Bartalucci C, Muccio M, Tiseo G, Muñoz P, Cesaretti M, et al. Comparative effectiveness of echinocandins and liposomal amphotericin B for fluconazole-resistant Candida parapsilosis bloodstream infections. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00355-25

BibTeX
@article{Vena2025,
  author = {Vena, Antonio and Bartalucci, Claudia and Muccio, Marco and Tiseo, Giusy and Muñoz, Patricia and Cesaretti, Mario and Di Pilato, Vincenzo and Marchese, Anna and Barbieri, Ramona and Forniti, Arianna and Giacobbe, Daniele Roberto and Limongelli, Alessandro and Lupetti, Antonella and Mikulska, Malgorzata and Salmanton-García, Jon and Soriano Martín, Ana and Taramasso, Lucia and Valerio, Maricela and Escribano, Pilar and Guinea, Jesus and Bouza, Emilio and Falcone, Marco and Bassetti, Matteo and ESCMID Fungal Infection Study Group (EFISG), ESCMID Fungal Infection Study Group (EFISG)},
  title = {Comparative effectiveness of echinocandins and liposomal amphotericin B for fluconazole-resistant Candida parapsilosis bloodstream infections},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00355-25}
}
Kostenlos starten →